Research Article| Volume 55, SUPPLEMENT 1, S83-S91, November 01, 2006

Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placebo- and conjugated estrogens-controlled study



      Aim of the present double-blind, randomized, placebo- and conjugated estrogens-controlled study was to assess efficacy and tolerability of BNO 1055, the ethanolic extract of Black cohosh (Actaea racemosa) in postmenopausal women suffering from estrogen deficiency symptoms.


      Ninety-five women were treated for 12 weeks with either BNO 1055 (daily dose corresponds to 40 mg of herbal drug), conjugated estrogens (CE, 0.6 mg/day), or placebo. The menopause rating scale (MRS) assessed climacteric complaints. Sweating episodes and sleeping behavior were evaluated from a patient diary. The change from baseline of the MRS total score after 12 weeks was defined as the primary efficacy endpoint. Changes from baseline were also analyzed for secondary endpoints including three MRS subscores (major climacteric complaints, somatic complaints, mental score), sweating episodes, and sleeping behavior. Thirty-three women had to be excluded from the intention-to-treat analysis due to protocol violations.


      BNO 1055 and CE reduced all estrogen deficiency symptoms and improved sleep quality equipotentially. Due to the small sample size the trial was considered as pilot study.


      This double-blind, CE- and placebo-controlled study demonstrated that BNO 1055 is able to reduce estrogen deficiency symptoms in the same degree as conjugated estrogens. The tolerability was good. Therefore, BNO 1055 might be another treatment alternative for menopausal complaints.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Willhite L.A.
        • O’Connell M.B.
        Urogenital atrophy: prevention and treatment.
        Pharmacotherapy. 2001; 21: 464-480
        • Hextall A.
        Oestrogens and lower urinary tract function.
        Maturitas. 2000; 36: 83-92
        • Bjarnason N.H.
        • Hassager C.
        • Christiansen C.
        Postmenopausal bone remodelling and hormone replacement.
        Climacteric. 1998; 1: 72-79
        • Greendale G.A.
        • Reboussin B.A.
        • et al.
        Symptom relief and side effects of postmenopausal hormone results from the postmenopausal estrogen/progestin interventions trial.
        Obstet Gynecol. 1998; 92: 982-988
        • O’Connell D.
        • Robertson J.
        • Henry D.
        • Gillespie W.
        A systemic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects.
        Climacteric. 1998; 1: 112-123
        • Samsioe G.
        Urogenital aging—a hidden problem.
        Am J Obstet Gynecol. 1998; 178: 245-249
        • Mikkola T.S.
        • Clarkson T.B.
        Estrogen replacement therapy, atherosclerosis, and vascular function.
        Cardiovasc Res. 2002; 53: 605-619
        • Herrington D.M.
        • Potvin Klein K.
        Cardiovascular trials of estrogen replacement therapy.
        Ann NY Acad Sci. 2001; 949: 153-162
        • Grodstein F.
        • Manson J.E.
        • Colditz G.A.
        • Willett W.C.
        • Speizer F.E.
        • Stampfer M.J.
        A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.
        Ann Intern Med. 2000; 133: 933-941
        • Hulley S.
        • Grady D.
        • et al.
        Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmeno-pausal women. Heart and estrogen/progestin replacement study (HERS) research group.
        JAMA. 1998; 280: 605-613
        • Rossouw J.E.
        • Anderson G.L.
        • et al.
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial.
        JAMA. 2002; 288: 321-333
        • Liehr J.G.
        Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development.
        Hum Reprod Update. 2001; 7: 273-281
        • Cauley J.A.
        • Norton L.
        • et al.
        Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple out-comes of raloxifene evaluation.
        Breast Cancer Res Treat. 2001; 65: 125-134
        • Southcott B.M.
        Carcinoma of the endometrium.
        Drugs. 2001; 61: 1395-1405
        • Feeley K.M.
        • Wells M.
        Hormone replacement therapy and the endometrium.
        J Clin Pathol. 2001; 54: 435-440
        • Borrelli F.
        • Ernst E.
        Cimicifuga racemosa: a systematic review of its clinical efficacy.
        Eur J Clin Pharmacol. 2002; 58: 235-241
        • Pepping J.
        Black cohosh: Cimicifuga racemosa.
        Am J Health Syst Pharm. 1999; 56: 1400-1402
      1. Saller R. Cimicifuga: Die Wirksamkeit ist dosisabhängig [Cimicifuga: efficacy response to the dose] Komitee Forschung Naturmedizin e.V. (KFN); 2005.

        • Osmers R.
        • Friede M.
        • Liske E.
        • Schnitker J.
        • Freudenstein J.
        • Henneicke-von Zepelin H.H.
        Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms.
        Obstet Gynecol. 2005; 105: 1074-1083
        • Frei-Kleiner S.
        • Schaffner W.
        • Rahlfs V.W.
        • Bodmer Ch
        • Birkhauser M.
        Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial.
        Maturitas. 2005; 51: 397-404
        • Wuttke W.
        • Seidlova-Wuttke D.
        • Gorkow C.
        The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers.
        Maturitas. 2003; 44: 67-77
        • Liske E.
        • Hanggi W.
        • Henneicke-von Zepelin H.H.
        • Boblitz N.
        • Wustenberg P.
        • Rahlfs V.W.
        Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhi-zoma): a 6-month clinical study demonstrates no systemic estrogenic effect.
        J Women Health Gend Based Med. 2002; 11: 163-174
        • Lehmann-Willenbrock E.
        • Riedel H.H.
        Klinische und endokrinologische Untersuchungen zur Therapie ovarieller Ausfallserscheinungen nach Hysterektomie unter Belassung der Adnexe.
        Zentralbl Gynakol. 1988; 110: 611-618
        • Stoll W.
        Phytotherapeutikum beeinflusst atrophisches Vaginalepithel: Doppelblindversuch Cimicifuga vs Östrogenpräparat [Phytopharmacon influences atrophic vaginal epithelium: double-blind study—Cimicifuga vs. estrogenic substances].
        Therapeuticum. 1987; 1: 23-31
        • Warnecke G.
        Beeinflussung klimakterischer Beschwerden durch ein Phytotherapeutikum. Erfolgreiche Therapie mit Cimicifuga-Monoextrakt.
        Med Welt. 1985; 36: 871-874
        • Anthony M.
        • Williams J.K.
        • Dunn B.K.
        What would be the properties of an ideal SERM?.
        Ann NY Acad Sci. 2001; 949: 261-278
        • Seidlova-Wuttke D.
        • Hesse O.
        • et al.
        Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta.
        Eur J Endocrinol. 2003; 149: 351-362
        • Düker E.M.
        • Kopanski L.
        • Jarry H.
        • Wuttke W.
        Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomized rats.
        Planta Med. 1991; 57: 420-424
        • Seidlova-Wuttke D.
        • Hesse O.
        • Jarry H.
        • Becker T.
        • Christoffel V.
        • Wuttke W.
        Pharmacology of Cimicifuga racemosa extract BNO 1055 in rats: bone, fat and uterus.
        Maturitas. 2003; 44: 39-50
        • Einer-Jensen N.
        • Zhao J.
        • Andersen K.P.
        • Kristoffersen K.
        Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats.
        Maturitas. 1996; 25: 149-153
        • Jarry H.
        • Metten M.
        • Spengler B.
        • Christoffel V.
        • Wuttke W.
        In vitro effects of the Cimicifuga racemosa extract BNO 1055.
        Maturitas. 2003; 44: 31-38
      2. CPMP/ICH/135/95. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Note for guidance on good clinical practice. Committee for Propietary Medicinal Product (CPMP), London; 1997.

      3. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Last amended by the 48th World Medical Assembly, Sommerset West, Republic of South Africa; 1996.

        • Dallal G.E.
        Design—power analysis and expected mean squares. A supplementary module for SYSTAT and SYSGRAPH.
        Systat Inc., Evanston, IL1988
        • Hauser G.A.
        • Huber I.C.
        • Keller P.J.
        • Lauritzen C.
        • Schneider H.P.G.
        Evaluation der klimakterischen Beschwerden (Menopause Rating Scale [MRS]).
        Zentralbl Gynakol. 1994; 116: 16-23
        • Wuttke W.
        • Gorkow C.
        • Seidlova-Wuttke D.
        Effects of Black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa and on various blood parameters in postmenopausal women: a double-blind, placebo- and conjugated estrogens-controlled study.
        Menopause. 2006; 13: 185-196
        • Kupperman H.S.
        • Wetchler B.B.
        • Blatt M.H.
        Contemporary therapy of the menopausal syndrome.
        JAMA. 1959; 171: 1627-1637
        • Schneider H.P.
        • Heinemann L.A.
        • Rosemeier H.P.
        • Potthoff P.
        • Behre H.M.
        The menopause rating scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36.
        Climacteric. 2000; 3: 50-58
      4. CHMP/EWP/021/97 Ref.1. The European Agency for the evaluation of medicinal products for human use. Committee for medicinal products for human use (CHMP). Guideline on clinical investigation of medicinal products for the treatment of hormone replacement therapy, Draft, London; 2005.